Ingredients Categories

News

Lonza reports strong performance

24 Jul 2015

In the first half of 2015, speciality ingredients and life sciences company Lonza has reported that its Specialty Ingredients and Pharma&Biotech segments both delivered a strong and improved performance and are on track to deliver their growth targets. Compared with the same period in 2014, sales growth of 6.1% to CHF 1,910 million in constant […]

Lonza reports strong performance

swiss-flag-alps-40093497In the first half of 2015, speciality ingredients and life sciences company Lonza has reported that its Specialty Ingredients and Pharma&Biotech segments both delivered a strong and improved performance and are on track to deliver their growth targets. Compared with the same period in 2014, sales growth of 6.1% to CHF 1,910 million in constant exchange rates (5.8% in reported currency) and CORE EBIT growth of 8.3% in constant exchange rates to CHF 261 million (7.9% in reported currency to CHF 260 million) are said to be coming from improved operational performance and the implementation of market-driven activities.

“Our customer- and market-orientation, as well as our positioning as a high-quality, innovative and reliable supplier, are all gaining momentum now, as our strong overall results confirm,” said Richard Ridinger, CEO of Lonza. “This steady improvement gives us the stability to look at further optimization of our portfolio and our asset

The company said that its good momentum in the first half of the year gives it the opportunity to further optimise its portfolio as it continues to implement higher-margin products and services, as well as to improve productivity in its manufacturing and business services networks. With its broad technology toolbox and increasing customer- and market-orientation, Lonza believes that its businesses have a stable product and project pipeline that will support future growth.

Based on the present macro-economic environment and current visibility, Lonza reiterated its full-year 2015 outlook with sales growth in reported currency compared with last year’s sales and a core EBIT growth of at least 5% in constant exchange rates.